<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5E0F5D03-52B4-4DF9-B505-C5A50E63CD33"><gtr:id>5E0F5D03-52B4-4DF9-B505-C5A50E63CD33</gtr:id><gtr:firstName>Vivian</gtr:firstName><gtr:surname>Li</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UP_1202%2F7"><gtr:id>04D15BCA-F209-4F27-A674-B85F8528E7BC</gtr:id><gtr:title>Wnt signalling pathway, intestinal stem cells and cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UP_1202/7</gtr:grantReference><gtr:abstractText>The Wnt signalling pathway controls myriad biological phenomena throughout development and adult life of all animals. The Wnt pathway plays a dual role in the intestine: it maintains crypt stem cell compartments and, when activated by mutation, it is the cause of colon cancer. Our goal is to understand Wnt pathway regulation in both aspects of intestinal biology. This will provide new insights for drug targeting of Wnt pathway in human cancers. We will use mouse models to study intestinal development and colorectal cancer in vivo. We combine the strength of basic (molecular approaches and mouse genetics) and clinical cancer research (tumour model and transplantation) to answer important biological questions. We are also experts in the use of state-of-the-art organoid culture technique to study gene function in vitro. Together we aim to generate a more complete picture of Wnt pathway, as it controls the biology of intestinal stem cells and cancer transformation.</gtr:abstractText><gtr:technicalSummary>In the adult intestine, crypts constitute the stem/progenitor cell compartments responsible for self-renewal of the epithelium. Wnt signals occur at the bottoms of proliferative crypts, the stem cell zone. This generates a signalling gradient from the stem cell zone to the upper trans-amplifying cells at the crypt-villus junction. The Wnt target Lgr5 has recently been found to mark intestinal stem cells at the crypt-base. Subsequent studies have unveiled additional genes such as Ascl2 and Rnf43 that are crucial for stem cell maintenance. Interestingly, all are Wnt target genes. Unlike most other Wnt targets showing crypt-wide expressions, these stem cell-Wnt target genes show exclusive stem cell expression. It is currently unknown what controls the identity of the stem cell versus its earliest, undifferentiated daughter cell. Loss of the negative Wnt pathway regulator APC occurs in most colorectal cancers (CRCs). We have previously identified a novel molecular mechanism by which APC controls the Wnt pathway. These studies predict one or more novel proteins to be required within the physiological APC complex. 
Our research aim is to answer important fundamental questions of intestinal development and CRC progression. The strategy leans heavily on proteomics and the generation of conditional knock-in/knockout mice. We delete or express candidate genes in adult mouse intestinal epithelium using inducible systems. In addition to the mouse work and proteomics, we also apply the advanced in vitro organic culture technique. These organoids, also called ?mini-guts?, grow three-dimensionally in matrigel to form intestinal crypt-villus budding structure encompassing all cellular lineages. We can genetically modify the organoids and study the morphological changes in vitro. This presents which a superior physiological readout compared to classical cell lines. Together, we aim to generate a more complete picture of Wnt pathway, as it controls the biology of intestinal stem cells and CRC.
In addition to the research on answering the fundemental questions, we are also interested in the clinical application of our work. We study the Wnt inhibitor treatment efficancy and efficiency using human CRC organoids. We will also carry out transplantation research with our collaborators to study stem cell therapy using organoid system. This will allow us to bring our basic research to the clinic for cancer therapy and regenerative medicine.</gtr:technicalSummary><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-02-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1085353</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>Intestinal tissue engineering</gtr:description><gtr:id>8586D04E-0933-4CBE-B2D6-A0FEC8FFEECD</gtr:id><gtr:impact>The project has been recently started. We have successfully competed for a joint medical PhD student Laween Meran through the NIHR UCL BRCs / Francis Crick Institute Clinical Research Training Fellowships Scheme to work on this project. Laween has optimised the human decellularisation as well as human intestinal organoid culture protocol. Preliminary data suggests that organoid seeding in acellular scaffold allow intestinal epithelial cell propagation and differentiation. The collaboration is multi-disciplinary to combine basic stem cell research with the clinic. This is a translational regenerative medicine project aiming to improve health quality of intestinal failure patients.</gtr:impact><gtr:outcomeId>AveQ2WMZFLM-1</gtr:outcomeId><gtr:partnerContribution>My collaborator works on the decellularisation protocol to obtain accellular intestinal scaffold obtained from human donor. They can also maintain the scaffold in the bioreactor and perform surgery to transplant the intestinal unit back to patients after the scaffold stem cell seeding.</gtr:partnerContribution><gtr:piContribution>We have established the in vitro intestinal organoids culture system of both mouse and human in NIMR. We plan to make use of the organoid stem cell culture to repopulate the decellularised intestinal scaffold generated by my collaborator. We will have to optimise the whole culture and seeding protocol. We will first perform the experiment in mouse and rat, and will finally proceed to human tissues.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Intestinal tissue engineering</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>DB75125B-8340-47A6-94D0-BE1E219D3CBE</gtr:id><gtr:impact>The potential benefit of this innovative treatment is large as it can be applicable not only to infants with Short Bowel Syndrome (SBS) as a consequence of bowel atresia, gastroschisis or necrotizing enterocolitis but also to children and adults affected who have developed SBS as a result of extensive intestinal resection from various intestinal disorders such as midgut volvulus, when the entire bowel can be lost because of torsion of its vascular supply. Parenteral nutrition and small bowel transplant are the only therapeutic options, but are associated with significant morbidity and mortality because of liver disease and the need for immunosuppression. Moreover, transplantation can only be offered to a small number of patients with SBS because of shortage of organs and it is a rare option for children because of size mismatch. The current intestine tissue engineering project has the potential of increasing the survival rate of SBS patients, improving the quality of life of patient and family, reducing long-term disability and reducing the cost of treatment for the family and society. The designed experiments will present a platform to develop intestinal regenerative medicine with impact on intensive care management, long-term intestinal support, and intestinal transplantation.</gtr:impact><gtr:outcomeId>ppYw3L7NHL5</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Crispr/Cas9 is the state-of-the-art genome editing technique to mutate genomic DNA endogenously. We have incorporated this technique to our organoid culture that we can genetically modified intestinal epithelium in organoids and study the functional role in vitro. We can also use the Crispr system to knockout genes in cell lines, which offers a clean and effective way to study functional role in vitro as compare to the conventional siRNA/shRNA method.</gtr:description><gtr:id>E860C7A7-1085-4C34-86C7-CAF12978CF6A</gtr:id><gtr:impact>Our Crispr/Cas9-coupled organoid screening represents a powerful tool to functionally shortlist our candidates by loss-of-function experiments. This can largely reduce the number of usage of animals, which support the 3R policy.</gtr:impact><gtr:outcomeId>f2WXC9FnRJz</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Crispr/Cas9</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have established the in vitro culture of intestinal organoids derived from both mouse and human. These organoids, also called &amp;quot;mini-guts&amp;quot;, grow 3-dimensionally in matrigel in a defined condition to form intestinal crypt-villus budding structure encompassing all cellular lineages.</gtr:description><gtr:id>345CFFBF-5F00-437D-95E0-5757EBD36F4B</gtr:id><gtr:impact>This is a fantastic system to study functional role of the candidate genes/pathways in the intestine in vitro. We can also use the system for genetic modification, drug screening and tissue engineering etc.
We are keen to promote our genome editing screening approach in organoids in vitro to perform high-throughput functional screening to minimise the use of animals.</gtr:impact><gtr:outcomeId>G1nwFM2ykrM</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Organoid culture</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have a collection of mouse strains to study functional roles of candidate genes/pathway in vivo in the intestine. We are also generating new conditional knockout mice to analyse the effect of gene deletion in the gut on stem cell and cancer transformation.</gtr:description><gtr:id>8D63BF4D-47DE-4C5D-9D0D-A0BA392DE4AA</gtr:id><gtr:impact>Animal studies are essential to provide relevant physiologically readout of genetic alterations and to confirm the functional data obtained in vitro work.</gtr:impact><gtr:outcomeId>TBvcDCSViPk</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Transgenic mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>DBFFC916-4169-4CA8-BDA6-9EB669991980</gtr:id><gtr:title>Reg4+ deep crypt secretory cells function as epithelial niche for Lgr5+ stem cells in colon.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c1a5aa10e0c9e94146926a0d5d3e63e"><gtr:id>2c1a5aa10e0c9e94146926a0d5d3e63e</gtr:id><gtr:otherNames>Sasaki N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>58b80379a72e55.24665316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BCBD45A-0054-4A35-80F5-2B16FD95BEC0</gtr:id><gtr:title>Intestinal Stem Cell Niche: The Extracellular Matrix and Cellular Components.</gtr:title><gtr:parentPublicationTitle>Stem cells international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/853210d37a776588f79872bb07bf6796"><gtr:id>853210d37a776588f79872bb07bf6796</gtr:id><gtr:otherNames>Meran L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a7dc52208d221.77554181</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40BD833B-6174-4203-80EC-8C95689DA980</gtr:id><gtr:title>NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7db1b373f7864413af24edeb44e89bed"><gtr:id>7db1b373f7864413af24edeb44e89bed</gtr:id><gtr:otherNames>Schwerd T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>5a7dc522ba5587.62776946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C69CC333-6630-4C2E-A8FA-42B1276E0D2D</gtr:id><gtr:title>Pak1 Kinase Maintains Apical Membrane Identity in Epithelia.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b74860e936f4da425901f70e68bf282e"><gtr:id>b74860e936f4da425901f70e68bf282e</gtr:id><gtr:otherNames>Aguilar-Aragon M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a9fc1c88368d2.34720053</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03953EF7-0ABF-4B0F-A75C-250E91C4CF00</gtr:id><gtr:title>Targeting Wnt signaling in colorectal cancer. A Review in the Theme: Cell Signaling: Proteins, Pathways and Mechanisms.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Cell physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d669222f950e2afdad2721ff169be766"><gtr:id>d669222f950e2afdad2721ff169be766</gtr:id><gtr:otherNames>Novellasdemunt L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0363-6143</gtr:issn><gtr:outcomeId>56b9c531b585d3.12943533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>519AC995-90BE-4FE4-A8FE-B7C907E472C0</gtr:id><gtr:title>Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f5948b5a7f162e349b3184da5420ba0"><gtr:id>5f5948b5a7f162e349b3184da5420ba0</gtr:id><gtr:otherNames>Wang K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>ffpnTjZmSjg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>706F58AA-ED7B-49D0-BD09-ADCDED71FD9C</gtr:id><gtr:title>USP7 Is a Tumor-Specific WNT Activator for APC-Mutated Colorectal Cancer by Mediating ?-Catenin Deubiquitination.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d669222f950e2afdad2721ff169be766"><gtr:id>d669222f950e2afdad2721ff169be766</gtr:id><gtr:otherNames>Novellasdemunt L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a7dc522623972.35950164</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UP_1202/7</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>